NMR spectroscopic structure elucidation of the products of the reaction of 3-(3-aryl-3-oxopropenyl)- chromen-4-ones with 1,2-phenylenediamine.

The reaction of 3-(3-aryl-3-oxopropenyl)chromen-4-ones with 1,2-phenylenediamine resulted in the unexpected formation of 10a-aryl-1,2,10,10a-tetrahydrobenzo-[4,5]-imidazo[1,2-a]pyridin-3-yl(2-hydroxyphenyl)-1-methanones. Their structure elucidation and complete 1H and 13C assignments have been performed by a combination of various one- and two-dimensional NMR experiments.

Talampanel improves the functional deficit after transient focal cerebral ischemia in rats. A 30-day follow up study.

The neuroprotective effect of talampanel, a negative allosteric modulator of alpha-amino-3-hydroxy-methyl-4-isoxazolyl-propionic acid (AMPA) receptors has been described previously. However, in these studies the histological changes and not the functional consequences of the brain damage were evaluated. The aim of present investigation was to analyze the sensorimotor function after stroke and to test the influence of talampanel (GYKI-53773, LY-300164) by 30-day monitoring in rats.

The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia.

Cerebroprotection after administration of glutamate receptor antagonists has been well documented. The present study is intended to determine whether the non-competitive alpha-amino-3-hydroxy-methyl-4-isoxazolyl-propionic acid (AMPA) receptor antagonist talampanel, known as antiepileptic drug, has neuroprotective effects in stroke models in rodents. The infarct size was measured in three models of stroke by 2,3,5-triphenyltetrazolium chloride staining.

Omeprazole and talampanel as two examples of retrometabolic drug design.

The goal of retrometabolic drug design is: "to design safe, locally active compounds with an improved therapeutic index". Here we describe two cases from our own practice, talampanel and omeprazole.

[The search for anti-ulcer agents at IDR].

2-Pyridyl-thioacetamide (2-PTA) was synthesized at IDR in 1968. This molecule showed strong antiulcer/antisecretory effects in animals and man by inhibiting the proton pump. Based on our work Astra developed omeprazole which is the No.